These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 24503127)

  • 1. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
    Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
    Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTPN3 mutations and HBV may exert synergistic effects in the origin of the intrahepatic cholangiocarcinoma.
    Cardinale V; Alvaro D
    Gastroenterology; 2014 Sep; 147(3):719-20. PubMed ID: 25075940
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.
    Nakanuma S; Tajima H; Okamoto K; Hayashi H; Nakagawara H; Onishi I; Takamura H; Kitagawa H; Fushida S; Tani T; Fujimura T; Kayahara M; Ohta T; Wakayama T; Iseki S; Harada S
    Int J Oncol; 2010 Apr; 36(4):793-800. PubMed ID: 20198321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
    Lu D; Han C; Wu T
    Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
    Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
    Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of glycogen synthase 2 in intrahepatic cholangiocarcinoma prognosis assessment and its influence on the activity of cancer cells.
    A S; Wu H; Wang X; Wang X; Yang J; Xia L; Xia Y
    Bioengineered; 2021 Dec; 12(2):12167-12178. PubMed ID: 34783271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
    Jin J; Ryu HS; Lee KB; Jang JJ
    PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.
    Talabnin C; Janthavon P; Thongsom S; Suginta W; Talabnin K; Wongkham S
    Hum Pathol; 2016 Jun; 52():47-54. PubMed ID: 26980022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTPN3 acts as a tumor suppressor and boosts TGF-β signaling independent of its phosphatase activity.
    Yuan B; Liu J; Cao J; Yu Y; Zhang H; Wang F; Zhu Y; Xiao M; Liu S; Ye Y; Ma L; Xu D; Xu N; Li Y; Zhao B; Xu P; Jin J; Xu J; Chen X; Shen L; Lin X; Feng XH
    EMBO J; 2019 Jul; 38(14):e99945. PubMed ID: 31304624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
    Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
    Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
    Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
    World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldolase A Enhances Intrahepatic Cholangiocarcinoma Proliferation and Invasion through Promoting Glycolysis.
    Li X; Yu C; Luo Y; Lin J; Wang F; Sun X; Gao Y; Tan W; Xia Q; Kong X
    Int J Biol Sci; 2021; 17(7):1782-1794. PubMed ID: 33994862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
    Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
    Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
    Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
    Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
    Yu WL; Yu G; Dong H; Chen K; Xie J; Yu H; Ji Y; Yang GS; Li AJ; Cong WM; Jin GZ
    J Gastroenterol; 2020 Dec; 55(12):1171-1182. PubMed ID: 33089343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
    Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
    J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis.
    Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y
    Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.